Daniel Reisner's practice focuses on patent and trade secret litigation, intellectual property licensing, and general complex commercial disputes. His intellectual property experience includes biotechnology, pharmaceuticals, ANDA litigations, medical devices, telecommunications, computers, plastic injection molding manufacture and aerospace systems.
Daniel has worked on numerous trials, has broad experience in all phases of litigation. He has been identified as a “Future Star” by the publisher of Institutional Investor and in the 2014 edition of Benchmark Litigation, and is recommended by The Legal 500 United States 2013. Examples of matters on which Daniel has worked include representation of Pfizer Inc in a patent infringement suit brought by the University of Rochester involving Celebrex®, a multibillion-dollar drug for the treatment of arthritis. The case resulted in victory for Pfizer with a decision by the Federal Circuit upholding the district court’s decision invalidating the patent-in-suit on a motion for summary judgment. In a subsequent suit against a generic, Daniel represented Pfizer in obtaining a victory at trial and affirmance on appeal. Another example is Daniel’s representation of Chiron Corporation in multiple actions involving its hepatitis C virus patents resulting in numerous dismissals of the opposing parties’ claims and defenses. He has also negotiated and drafted numerous patent and technology licenses for clients such as Novartis Pharmaceuticals Corporation, Pfizer and others.
Daniel also represents clients in telecommunications- and computer-related patent disputes. The technologies involved aspects of broadband data and video transmission, coaxial cable and optical data transmission, headends, data centers, computer networking, satellite communication, NTSC, ATSC, MPEG and DOCSIS standards, videotex, handheld computing, memory, peripherals and microprocessors.
Daniel is the co-editor and a principal contributing author of Pharmaceutical and Biotech Patent Law, published by the Practising Law Institute, and frequently speaks and writes about a variety of patent and licensing issues.